BRAF and non-small cell lung carcinoma: Since then, TKIs are used as the first‐line treatment for patients with NSCLC with driver mutations in EGFR, ALK, ROS1, and BRAF. Currently, government‐approved in vitro diagnosis tests (IVDs) are utilized to detect individual targetable driver gene mutations in NSCLC.